Cutera (CUTR) 10-Q 10 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 06, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	000-50644
Entity Registrant Name	Cutera, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0492262
Entity Address, Address Line One	3240 Bayshore Blvd.
Entity Address, City or Town	Brisbane
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94005
City Area Code	415
Local Phone Number	657-5500
Title of 12(b) Security	Common Stock ($0.001 par value)
Trading Symbol	CUTR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,163,389
Entity Central Index Key	0001162461
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 57,732	$ 164,164
Marketable investments	74,047	0
Accounts receivable, net of allowance for credit losses of $1,093 and $899, respectively	33,169	31,449
Inventories	51,680	39,503
Other current assets and prepaid expenses	20,156	14,545
Total current assets	236,784	249,661
Property and equipment, net	3,009	3,019
Deferred tax asset	737	778
Operating lease right-of-use assets	14,330	14,627
Goodwill	1,339	1,339
Other long-term assets	9,792	10,169
Restricted cash	700	700
Total assets	266,691	280,293
Current liabilities:
Accounts payable	13,646	7,891
Accrued liabilities	48,044	54,100
Operating lease liabilities	2,628	2,419
Deferred revenue	9,719	9,490
Total current liabilities	74,037	73,900
Deferred revenue, net of current portion	1,345	1,335
Operating lease liabilities, net of current portion	13,007	13,483
Convertible notes, net of unamortized debt issuance costs of $3,788 and $4,007, respectively	134,462	134,243
Other long-term liabilities	680	763
Total liabilities	223,531	223,724
Commitments and Contingencies (Note 12)
Stockholders’ equity:
Common stock, $0.001 par value; authorized: 50,000,000 shares; issued and outstanding: 18,132,949 and 17,995,344 shares at March 31, 2022 and December 31, 2021, respectively	18	18
Additional paid-in capital	116,468	114,724
Accumulated other comprehensive loss	(11)	0
Accumulated deficit	(73,315)	(58,173)
Total stockholders’ equity	43,160	56,569
Total liabilities and stockholders’ equity	$ 266,691	$ 280,293

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for credit loss, current	$ 1,093	$ 899
Unamortized debt issuance costs	$ 3,788	$ 4,007
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock authorized (in shares)	50,000,000	50,000,000
Common stock issued (in shares)	18,132,949	17,995,344
Common stock outstanding (in shares)	18,132,949	17,995,344

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net revenue:
Total net revenue	$ 58,014	$ 49,668
Cost of revenue:
Total cost of revenue	26,226	21,958
Gross profit	31,788	27,710
Operating expenses:
Sales and marketing	24,944	15,068
Research and development	6,499	4,112
General and administrative	13,502	7,365
Total operating expenses	44,945	26,545
(Loss) income from operations	(13,157)	1,165
Interest and other expense, net:
Amortization of debt issuance costs	(219)	(52)
Interest on convertible notes	(778)	(191)
Other expense, net	(755)	(1,023)
Total interest and other expense, net	(1,752)	(1,266)
Loss before income taxes	(14,909)	(101)
Income tax expense	233	258
Net loss	$ (15,142)	$ (359)
Net loss per share:
Basic (USD per share)	$ (0.84)	$ (0.02)
Diluted (USD per share)	$ (0.84)	$ (0.02)
Weighted-average number of shares used in per share calculations:
Basic (in shares)	18,080	17,768
Diluted (in shares)	18,080	17,768
Total product revenue
Net revenue:
Total net revenue	$ 52,066	$ 43,551
Cost of revenue:
Total cost of revenue	22,912	18,331
Service
Net revenue:
Total net revenue	5,948	6,117
Cost of revenue:
Total cost of revenue	$ 3,314	$ 3,627

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (15,142)	$ (359)
Available-for-sale investments
Net change in unrealized loss on available-for-sale investments	(11)	0
Other comprehensive loss, net of tax	(11)	0
Comprehensive loss	$ (15,153)	$ (359)

Consolidated Statements of Chan

Consolidated Statements of Changes In Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Balance (in shares) at Dec. 31, 2020		17,679,232
Balance at Dec. 31, 2020	$ 56,880	$ 18	$ 117,097	$ (60,235)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		24,090
Exercise of stock options	396		396
Purchase of capped call	(16,134)		(16,134)
Issuance of common stock in settlement of restricted and performance stock unites, net of shares withheld for employee taxes (in shares)		98,604
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes	(999)		(999)
Stock-based compensation expense	1,846		1,846
Net loss	(359)			(359)
Net change in unrealized loss on available-for-sale investments	0
Balance (in shares) at Mar. 31, 2021		17,801,926
Balance at Mar. 31, 2021	$ 41,630	$ 18	102,206	(60,594)	0
Balance (in shares) at Dec. 31, 2021	17,995,344	17,995,344
Balance at Dec. 31, 2021	$ 56,569	$ 18	114,724	(58,173)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	7,459	7,459
Exercise of stock options	$ 151		151
Purchase of capped call	0
Issuance of common stock in settlement of restricted and performance stock unites, net of shares withheld for employee taxes (in shares)		130,146
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes	(2,450)		(2,450)
Stock-based compensation expense	4,043		4,043
Net loss	(15,142)			(15,142)
Net change in unrealized loss on available-for-sale investments	$ (11)				(11)
Balance (in shares) at Mar. 31, 2022	18,132,949	18,132,949
Balance at Mar. 31, 2022	$ 43,160	$ 18	$ 116,468	$ (73,315)	$ (11)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (15,142)	$ (359)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Stock-based compensation	4,043	1,846
Depreciation and amortization	427	361
Amortization of contract acquisition costs	652	545
Amortization of debt issuance costs	219	52
Impairment of capitalized cloud computing costs	0	182
Change in deferred tax asset	41	45
Provision for excess and obsolete inventories	358	193
Provision for credit losses	192	218
Loss (gain) on sale of property and equipment	14	(59)
Change in right-of-use assets	638	604
Changes in assets and liabilities:
Accounts receivable	(1,912)	(2,407)
Inventories	(12,535)	(6,214)
Other current assets and prepaid expenses	(5,611)	(1,560)
Other long-term assets	(385)	(500)
Accounts payable	5,755	(1,653)
Accrued liabilities	(5,989)	10,022
Operating lease liabilities	(608)	(563)
Deferred revenue	239	500
Net cash (used in) provided by operating activities	(29,604)	1,253
Cash flows from investing activities:
Acquisition of property, equipment, and software	(321)	(101)
Proceeds from disposal of property and equipment	0	52
Purchase of marketable investments	(74,058)	0
Net cash used in investing activities	(74,379)	(49)
Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan	151	396
Purchase of capped call	0	(16,134)
Proceeds from issuance of convertible notes	0	138,250
Payment of issuance costs of convertible notes	0	(4,717)
Taxes paid related to net share settlement of equity awards	(2,450)	(999)
Payments on finance lease obligations	(150)	(115)
Net cash (used in) provided by financing activities	(2,449)	116,681
Net (decrease) increase in cash, cash equivalents and restricted cash	(106,432)	117,885
Cash, cash equivalents, and restricted cash at beginning of period	164,864	47,047
Cash, cash equivalents, and restricted cash at end of period	58,432	164,932
Supplemental disclosure of non-cash items:
Assets acquired under finance lease	57	25
Assets acquired under operating lease	320	123
Debt issuance costs accrued	0	452
Supplemental disclosure of cash flow information:
Cash paid for interest	1,577	14
Income tax paid	$ 1,100	$ 458

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Description of Operations and Principles of Consolidation Cutera, Inc. (“Cutera” or the “Company”) is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. The Company develops, manufactures, distributes, and markets energy-based product platforms for use by medical practitioners, enabling them to offer safe and effective aesthetic treatments to their customers. The Company currently markets the following system platforms: AviClear, enlighten, excel, Secret PRO, Secret RF, truSculpt and xeo . Several of the Company’s systems offer multiple hand pieces and applications, providing customers the flexibility to upgrade their systems. The sales of (i) systems, system upgrades, and hand pieces (collectively “Systems” revenue); (ii) replacement hand pieces, Titan, truSculpt 3 D, truSculpt iD and truSculpt flex cycle refills, as well as single use disposable tips applicable to Secret PRO and Secret RF (“Consumables” revenue); and (iii) the distribution of third party manufactured skincare products (“Skincare” revenue); are collectively classified as “Products” revenue. In addition to Product revenue, the Company generates revenue from the sale of post-warranty service contracts, parts, detachable hand piece replacements (except for Titan, truSculpt 3D, truSculpt iD and truSculpt flex) and service labor for the repair and maintenance of products that are out of warranty, all of which are collectively classified as “Service” revenue. In March 2022, the Company received the U.S. Food and Drug Administration's 510(k) clearance of the AviClear acne treatment device ("AviClear"). AviClear is a laser treatment that offers a safe, prescription-free solution for acne. AviClear will be rolled out to physicians in the United States throughout 2022. The Company’s corporate headquarters and U.S. operations are located in Brisbane, California, where the Company conducts manufacturing, warehousing, research and development, regulatory, sales and marketing, service, and administrative activities. The Company markets, sells and services its products through its sales and service employees in North America (including Canada), Australia, Austria, Belgium, France, Germany, Hong Kong, Japan, the Netherlands, Spain, Switzerland, and the United Kingdom. Sales and services outside of these direct markets are made through a worldwide distributor network in over 42 countries. The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Basis of Presentation In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements included in this report reflect all adjustments necessary for a fair statement of its condensed consolidated statements of financial position as of March 31, 2022 and December 31, 2021, and its condensed consolidated statements of results of operations, comprehensive income (loss), changes in equity, and cash flows for the three months ended March 31, 2022, and 2021. The December 31, 2021 condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (“GAAP”). The results for interim periods are not necessarily indicative of results for the entire year or any other interim period. Presentation of certain prior year balances have been updated to conform with current year presentation. All intercompany accounts and transactions have been eliminated upon consolidation. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s previously filed audited financial statements and the related notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2022. Risks and Uncertainties The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company's products, stability of global financial markets, cybersecurity breaches and other disruptions that could compromise the Company’s information or results, business disruptions that are caused by natural disasters or pandemic events, management of international activities, competition from substitute products and larger companies, ability to obtain and maintain regulatory approvals, government regulations and oversight, patent and other types of litigation, ability to protect proprietary technology from counterfeit versions of the Company's products, strategic relationships and dependence on key individuals. The COVID-19 outbreak and related variants have negatively affected the United States and global economies. The spread of the coronavirus has impacted the global economy broadly in 2021 and 2020, including restrictions on travel, shifting work forces to work remotely and quarantine policies put into place by businesses and governments, had a material economic effect on the Company’s business during the year ended December 31, 2021. Healthcare facilities in many countries effectively banned elective procedures and this had a significant impact on the Company. Many of the Company’s products are used in aesthetic elective procedures and as such, the bans on elective procedures substantially reduced the Company’s sales and marketing efforts in the early months of the pandemic and led the Company to implement cost control measures. Although the Company’s revenues and profits have improved as the economic outlook improved in 2021 and into 2022, the COVID-19 outbreak continues to be fluid, and the long-term impact on the Company's business due to COVID-19 is still uncertain. The Company cannot presently predict the scope and severity of any impacts in future periods from business shutdowns or disruptions due to the COVID-19 pandemic, but the impact on economic activity including the possibility of recession or financial market instability could have a material adverse effect on the Company’s business, revenue, operating results, cash flows and financial condition. The Company continues to assess whether any impairment of its goodwill or its long-lived assets has occurred and has determined that no charges were necessary during the three months ended March 31, 2022. The Company will continue to monitor future conditions important to its assessment of potential impairment of its long-lived assets and goodwill, including the impacts of the COVID–19 pandemic and other ongoing impacts which are subject to uncertainty. In 2021, the Company experienced a significant increase in sales of skincare products under the exclusive distribution agreement with ZO Skin Health, Inc. (“ZO”), which allows the Company to sell ZO’s skincare products in Japan. The reason for the increase in skincare products sales may have been the result of the COVID-19 pandemic changing customers’ spending habits, resulting in customers purchasing aesthetic treatments that were able to be applied at home, due to limitations on in-person aesthetic procedures. Future growth in sales of skincare products depends on customers maintaining spending habits adopted during the COVID-19 pandemic. If customers revert to original spending habits after the COVID-19 pandemic, such changes may have a material adverse effect on the Company’s revenue, operating results, and cash flows. Accounting Policies These unaudited condensed consolidated financial statements are prepared in accordance with the rules and regulations of the SEC applicable to interim financial statements. While these statements reflect all normal recurring adjustments that are, in the opinion of management, necessary for fair presentation of the results of the interim period, they do not include all of the information and footnotes required by GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the financial statement disclosures in its annual report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022. The Company uses the same accounting policies in preparing quarterly and annual financial statements. Unless otherwise noted, amounts presented within the notes to condensed consolidated financial statements refer to the Company’s continuing operations. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenue and expenses during the reported periods. Actual results could differ materially from those estimates. On an ongoing basis, management evaluates its estimates, including those related to warranty obligations, sales commission, allowance for credit losses, sales allowances, fair value of investments, valuation of inventories, fair value of goodwill, useful lives of property and equipment, impairment testing for long-lived-assets, implicit and incremental borrowing rates related to the Company’s leases, variables used in calculating the fair value of the Company's equity awards, expected achievement of performance based vesting criteria, management performance bonuses, assumptions used in operating and sales-type lease classification, the standalone selling price of the Company's products and services, the period of benefit used to capitalize and amortize contract acquisition costs, variable consideration, contingent liabilities, recoverability of deferred tax assets, residual value of leased equipment, lease term and effective income tax rates. Management bases estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes , to remove certain exceptions and improve consistency of application, including, among other things, requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The Company adopted this guidance starting January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial position and results of operations. In August 2020, the FASB issued ASU No. 2020-6, Debt – Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815), to simplify the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the amendment, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the computation of diluted earnings per share. The Company early adopted the guidance on a prospective basis effective January 1, 2021. See Note 13 – Debt.

Cash, Cash Equivalents and Mark

Cash, Cash Equivalents and Marketable Investments	3 Months Ended
	Mar. 31, 2022
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Marketable Investments	Cash, Cash Equivalents and Marketable Investments The Company invests its cash primarily in money market funds and in highly liquid debt instruments of U.S. federal and municipal governments and their agencies. All highly liquid investments with stated maturities of three months or less from date of purchase are classified as cash equivalents; all highly liquid investments with stated maturities of greater than three months are classified as marketable investments. The majority of the Company’s cash and investments are held in U.S. banks and U.S. Treasuries. The Company's foreign subsidiaries maintain a limited amount of cash in their local banks to cover their short term operating expenses. The Company determines the appropriate classification of its investments in marketable securities at the time of purchase and re-evaluates such designation at each balance sheet date. The Company’s marketable securities have been classified and accounted for as available-for-sale securities. Investments with remaining maturities of more than one year are viewed by the Company as available to support current operations and are classified as current assets under the caption marketable investments in the accompanying condensed consolidated balance sheets. Investments in available-for-sale debt securities are measured at fair value under the guidance in ASC 320. Credit losses on impaired available-for-sale debt securities are recognized through an allowance for credit losses. Under ASC 326, credit losses recognized on an available-for-sale debt security should not reduce the net carrying amount of the available-for-sale debt security below its fair value. Any changes in fair value unrelated to credit are recognized as an unrealized gain or loss in other comprehensive income. The following table summarizes the Company's cash and cash equivalents and marketable investments (in thousands): Gross Gross Fair Amortized Unrealized Unrealized Market March 31, 2022 Cost Gains Losses Value Cash and cash equivalents $ 57,732 $ — $ — $ 57,732 Non-current restricted cash 700 — — 700 Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows 58,432 — — 58,432 Marketable investments - U.S. Treasury 74,058 — (11) 74,047 Total $ 132,490 $ — $ (11) $ 132,479 Gross Gross Fair Amortized Unrealized Unrealized Market December 31, 2021 Cost Gains Losses Value Cash and cash equivalents $ 164,164 $ — $ — $ 164,164 Non-current restricted cash 700 — — 700 Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows $ 164,864 $ — $ — $ 164,864 At March 31, 2022 and December 31, 2021, the net unrealized losses were $11 thousand and nil, respectively, and were related to interest rate changes on available-for-sale marketable investments. The Company has concluded that it is more-likely-than-not that the securities will be held until maturity or the recovery of their cost basis. No securities were in an unrealized loss position for more than 12 months. T he cash is restricted to support an outstanding letter of credit for $0.7 million provided to a supplier. The following table summarizes the contractual maturities of the Company’s available-for-sale securities, classified as marketable investments, as of March 31, 2022 (in thousands): March 31, 2022 Amount Due in less than one year $ 74,058

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures certain financial assets at fair value, including cash and cash equivalents. The fair value hierarchy contains the following three levels of inputs that may be used to measure fair value, in accordance with ASC 820: • Level 1: inputs, which include quoted prices in active markets for identical assets or liabilities; • Level 2: inputs, which include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and • Level 3: inputs, which include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies, or similar valuation techniques, as well as significant management judgment or estimation. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considering counterparty credit risk in its assessment of fair value. As of March 31, 2022, financial assets measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above were as follows (in thousands): March 31, 2022 Level 1 Level 2 Level 2 Cash equivalents: Money market funds $ 948 $ — $ — Marketable investments: Available-for-sale securities 74,047 — — Total $ 74,995 $ — $ — At December 31, 2021, the Company had no money market funds or marketable investments. See Note 13 - Debt for the carrying amount and estimated fair value of the Company’s convertible notes due 2026.

Balance Sheet Details

Balance Sheet Details	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Details	Balance Sheet Details Inventories As of March 31, 2022 and December 31, 2021, inventories consist of the following (in thousands): March 31, December 31, Raw materials $ 31,134 $ 24,035 Work in process 2,902 2,124 Finished goods 17,644 13,344 Total $ 51,680 $ 39,503 Accrued Liabilities As of March 31, 2022 and December 31, 2021, accrued liabilities consist of the following (in thousands): March 31, December 31, Bonus and payroll-related accruals $ 16,639 $ 21,649 Sales and marketing accruals 3,678 4,808 Accrued inventory in transit 3,530 4,265 Product warranty 3,874 3,947 Accrued sales tax 9,853 9,110 Other accrued liabilities 10,470 10,321 Total $ 48,044 $ 54,100

Product Warranty

Product Warranty	3 Months Ended
	Mar. 31, 2022
Product Warranties Disclosures [Abstract]
Product Warranty	Product Warranty The Company has a direct field service organization in North America (including Canada). Internationally, the Company provides direct service support in Australia, Austria, Belgium, France, Germany, Hong Kong, Japan, the Netherlands, Spain, Switzerland, and the United Kingdom. In several other countries, where the Company does not have a direct presence, the Company provides service through a network of distributors and third-party service providers. After the original warranty period, maintenance and support are offered on an extended service contract basis or on a time and materials basis. The Company provides the estimated cost to repair or replace products under standard warranty at the time of sale. Costs incurred in connection with extended service contracts are generally recognized at the time when costs are incurred. The following table provides the changes in the product warranty accrual for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended 2022 2021 Beginning Balance $ 3,947 $ 2,908 Add: Accruals for warranties issued during the period 1,462 1,525 Less: Settlements made during the period (1,535) (1,082) Ending Balance $ 3,874 $ 3,351

Deferred Revenue

Deferred Revenue	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Deferred Revenue	Deferred Revenue The Company records deferred revenue when revenue is to be recognized subsequent to invoicing. For extended service contracts, the Company generally invoices customers at the beginning of the extended service contract term. The Company’s extended service contracts typically have one The following table provides changes in the deferred revenue balance for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended 2022 2021 Beginning balance $ 10,825 $ 11,237 Add: Payments received 4,864 4,929 Less: Revenue (458) (445) Less: Revenue recognized from beginning balance (4,167) (3,984) Ending balance $ 11,064 $ 11,737 Costs for extended service contracts were $1.7 million and $2.0 million for the three months ended March 31, 2022, and March 31, 2021, respectively.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services. The Company’s performance obligations are satisfied either over time or at a point in time. Revenue from performance obligations that are transferred to customers over time accounted for approximately and 7% and 12% of the Company's total revenue for the three months ended March 31, 2022, and March 31, 2021, respectively. The Company has certain systems sales arrangements that contain multiple products and services. For these bundled sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct. The Company’s products and services are distinct if a customer can benefit from the product or service on its own or with other resources that are readily available to the customer, and if the Company’s promise to transfer the products or service to the customer is separately identifiable from other promises in the sale arrangements. The Company’s system sale arrangements can include all or a combination of the following performance obligations: the system and software license (considered as one performance obligation), system accessories (hand pieces), training, other accessories, extended service contracts, marketing services, and time and materials services. For the Company’s system sale arrangements that include an extended service contract, the period of service commences at the expiration of the Company’s standard warranty offered at the time of the system sale. The Company considers the extended service contracts terms in the arrangements that are legally enforceable to be performance obligations. Other than extended service contracts and marketing services, which are satisfied over time, the Company generally satisfies all performance obligations at a point in time. Systems, system accessories (hand pieces), service contracts, training, and time and materials services are also sold on a stand-alone basis, and these performance obligations are satisfied at a point in time. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation on a relative standalone selling price basis. Significant Judgments The determination of whether two or more contracts entered into at or near the same time with the same customer should be combined and accounted for as one contract may require the use of significant judgment. In making this determination, the Company considers whether the contracts are negotiated as a package with a single commercial objective, have price interdependencies, or promise goods or services that represent a single performance obligation. While the Company’s purchase agreements do not provide customers with a contractual right of return, the Company maintains a sales allowance to account for potential returns or refunds as a reduction in transaction price at the time of sale. The Company estimates sales returns and other variable consideration based on historical experience. The Company determines the standalone selling price ("SSP") for each performance obligation as follows: • Systems: The SSPs for systems are based on directly observable sales in similar circumstances to similar customers. • Extended warranty/Service contracts: SSP is based on observable price when sold on a standalone basis (by customer type). Nature of Products and Services Systems Systems revenue is generated from the sale of systems and from the sale of upgrades to existing systems. A system consists of a console that incorporates a universal graphic user interface, a laser or other energy-based module, control system software and high voltage electronics, as well as one or more hand pieces. In certain applications, the laser or other energy-based module is contained in the hand piece rather than within the console. The system or upgrade and the right to use the embedded software represent a single performance obligation as the software license is integral to the functionality of the system or upgrade. For systems sold directly to end-customers that are credit approved, revenue is recognized when the Company transfers control to the end-customer, which occurs when the product is shipped to the customer or when the customer receives the product, depending on the nature of the arrangement. When collectability is not established in advance of receipt of payment from the customer, revenue is recognized upon the later of the receipt of payment or the satisfaction of the performance obligation. For systems sold through credit approved distributors, revenue is recognized upon shipment to the distributor. The Company typically receives payment for its system consoles and other accessories within 30 days of shipment. Certain international distributor arrangements allow for longer payment terms. Skincare products The Company sells third-party manufactured skincare products in Japan. The skincare products are purchased from a third-party manufacturer and sold to medical offices and licensed physicians. The Company warrants that the skincare products are free of significant defects in workmanship and materials for 90 days from shipment. The Company acts as the principal in this arrangement, as the Company determines the price to charge customers for the skincare products and controls the products before they are transferred to the customer. The Company recognizes revenue for skincare products upon shipment. Consumables and other accessories The Company classifies its customers' purchases of replacement cycles for truSculpt iD and truSculpt flex, as well as replacement hand pieces, x eo and truSculpt 3D hand pieces, and single use disposable tips applicable to Secret PRO, and Secret RF, as Consumable revenue, which provides the Company with a source of recurring revenue from existing customers. The Secret RF product single use disposable tips must be replaced after every treatment. The Company’s systems offer multiple hand pieces and applications, which allow customers to upgrade their systems. Extended contract services The Company offers post-warranty services to its customers through extended service contracts that cover parts and labor for terms of one Training Sales of systems to customers include training on the use of the system to be provided within 180 days of purchase. The Company considers training a separate performance obligation as customers can immediately benefit from the training together with the customer’s system. Training is also sold separately from systems. The Company recognizes revenue for training when the training is provided. Loyalty Program The Company has a customer loyalty program for qualified customers located in the U.S., Canada, Australia and New Zealand. Under the loyalty program, based on their purchasing levels, customers accumulate points that can be redeemed for such rewards as the right to attend the Company’s advanced training event for truSculpt , or a ticket for the Company’s annual forum. A customer’s account must be in good standing to receive the benefits of the rewards program. Rewards are earned on a quarterly basis and must be used in the following quarter. All unused rewards are forfeited. The fair value of the reward earned by loyalty program members is included in accrued liabilities and recorded as a reduction of net revenue at the time the reward is earned. As of March 31, 2022 and December 31, 2021, the liability for the loyalty program included in accrued liabilities was $0.3 million and $0.5 million, respectively. Deferred Sales Commissions Incremental costs of obtaining a contract, which consist of commissions and related payroll taxes, are deferred and amortized on a straight-line basis over an expected period of benefit estimated to be two Total capitalized costs as of March 31, 2022 and December 31, 2021 were $3.5 million and $4.2 million, respectively, and are included in Other long-term assets in the Company’s condensed consolidated balance sheet. Amortization expense for these assets was $0.7 million and $0.5 million during the three months ended March 31, 2022, and March 31, 2021, respectively. The amortization related to these capitalized costs is included in sales and marketing expense in the Company’s condensed consolidated statement of operations.

Stockholders' Equity and Stock-

Stockholders' Equity and Stock-based Compensation Expense	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stockholders' Equity and Stock-based Compensation Expense	Stockholders ’ Equity and Stock-based Compensation Expense The Company’s equity incentive plans are broad-based, long-term programs intended to attract and retain talented employees and align stockholder and employee interests. The 2019 Equity Incentive Plan (the "2019 Plan") provides for the grant of incentive stock options, non-statutory stock options, restricted stock units (“RSUs”), performance stock units ("PSUs"), and other stock or cash awards. The Company’s Board of Directors granted the Company's executive officers, senior management and certain employees 90,658 PSUs during the three months ended March 31, 2022. These PSUs vest subject to the Company’s achievement of certain operational goals for the 2022 fiscal year related to product and commercial milestones. In addition, there is a service requirement related to half of the granted quantity that requires the grant recipient to provide one year of service subsequent to the milestone achievement date. The Company’s Board of Directors also granted its executive officers and senior management 95,761 RSUs and 207,062 non-qualified stock options (“NQs”) during the three months ended March 31, 2022 . The RSUs and NQs vest over four years with one-fourth vesting on the first anniversary of the vesting commencement date of January 1, 2022 and 1/36 of the remaining underlying shares vest each month thereafter. Activity under the Company's equity incentive plans is summarized as follows: Shares Balance, December 31, 2021 947,347 RSUs granted (95,761) PSUs granted (90,658) Options granted (207,062) Stock awards canceled / forfeited / expired 22,568 Options canceled / forfeited / expired 2,072 Balance, March 31, 2022 578,506 Options Outstanding Number of Weighted- Weighted Average Remaining Term Balance, December 31, 2021 287,175 $ 25.89 4.92 Options granted 207,062 $ 35.34 Options exercised (7,459) $ 20.24 Options canceled / forfeited / expired (2,072) $ 32.87 Balance, March 31, 2022 484,706 $ 29.99 6.88 Stock Awards Outstanding Number of Awards Outstanding Weighted Average Grant Date Fair Value per Share Balance, December 31, 2021 1,032,904 $ 35.00 RSUs granted 95,761 $ 39.53 PSUs granted 90,658 $ 34.16 Awards released (190,967) $ 28.04 Stock awards canceled / forfeited / expired (21,081) $ 40.00 Balance, March 31, 2022 1,007,275 $ 36.57 Stock-based Compensation Expense Stock-based compensation expense by department recognized during the three months ended March 31, 2022 and 2021 was as follows (in thousands): Three Months Ended 2022 2021 Cost of revenue $ 459 $ 144 Sales and marketing 576 721 Research and development 980 301 General and administrative 2,028 680 Total stock-based compensation expense $ 4,043 $ 1,846

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share On January 1, 2021, the Company adopted the accounting standard update to simplify the accounting for convertible debt instruments. The Company now uses the if converted method for its convertible notes in calculating the diluted net income (loss) per share, and includes the effect of potential share settlement for the convertible notes, if the effect is dilutive. Basic earnings per share (“EPS”) is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method and the if-converted method. Dilutive potential common shares include outstanding stock options, restricted stock units, performance stock units, ESPP shares and conversion shares under the convertible notes. The diluted EPS is computed with the assumption that the Company will settle the convertible debt in shares, rather than cash. As of March 31, 2022, the Company’s convertible notes were potentially convertible into 4,167,232 shares of common stock. The Company used the if-converted method to calculate the potential dilutive effect of the conversion spread on diluted net income per share for the three months ended March 31, 2022. The denominator for diluted net income (loss) per share does not include any effect from the capped call transactions the Company entered into concurrently with the issuance of the convertible notes, as this effect would be anti-dilutive. In the event of conversion of a Convertible note, shares delivered to the Company under the capped call will offset the dilutive effect of the shares that the Company would issue under the convertible notes. In the three months ended March 31, 2022, the “if-converted method” was not applied as the effect would have been anti-dilutive. For the three months ended March 31, 2022, a basic loss per common share and diluted loss per common share are the same in each respective period as the inclusion of any potentially issuable shares would be anti-dilutive. The following table sets forth the computation of basic and diluted net loss and the weighted average number of shares used in computing basic and diluted net loss per share (in thousands, except per share data): Three Months Ended 2022 2021 Numerator: Net loss used in calculating net loss per share, basic and diluted $ (15,142) $ (359) Denominator: Weighted average shares of common stock outstanding used in computing net loss per share, basic 18,080 17,768 Dilutive effect of incremental shares and share equivalents: Options — — RSUs — — PSUs — — ESPP — — Weighted average shares of common stock outstanding used in computing net loss per share, diluted 18,080 17,768 Net loss per share: Net loss per share, basic $ (0.84) $ (0.02) Net loss per share, diluted $ (0.84) $ (0.02) The following numbers of shares outstanding, prior to the application of the treasury stock method and the if-converted method, were excluded from the computation of diluted net loss per common share for the periods presented because including them would have had an anti-dilutive effect (in thousands): Three Months Ended 2022 2021 Capped call 4,167 4,167 Convertible notes 4,167 4,167 Options to purchase common stock 485 245 Restricted stock units 526 585 Performance stock units 482 92 Employee stock purchase plan shares 32 30 Total 9,859 9,286

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended March 31, 2022, the Company's income tax expense was $0.2 million, compared to the tax expense of $0.3 million for the three months ended March 31, 2021. The Company's income tax expense for the three months ended March 31, 2022 and 2021, is due to income taxes in foreign jurisdictions. The Company continues to maintain a full valuation allowance on its U.S. deferred tax assets.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	LeasesThe Company is a party to certain operating and finance leases for vehicles, office space and storage facilities. The Company’s operating leases consist of office space, as well as storage facilities and finance leases consist of automobiles. The Company’s leases generally have remaining terms of one The Company determines if a contract contains a lease at inception. Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent the right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, the Company estimates the incremental secured borrowing rates corresponding to the maturities of the leases. The Company based the rate estimates on prevailing financial market conditions, credit analysis, and management judgment. The Company recognizes expense for these leases on a straight-line basis over the lease term. Additionally, tenant incentives used to fund leasehold improvements are recognized when earned and reduce the Company’s right-of-use (“ROU”) asset related to the lease. These are amortized through the ROU asset as reductions of expense over the lease term. Supplemental balance sheet information related to leases was as follows (in thousands): Leases Classification March 31, December 31, Assets Right-of-use assets Operating lease assets $ 14,330 $ 14,627 Finance lease Property and equipment, net 403 392 Total leased assets $ 14,733 $ 15,019 Liabilities Classification March 31, December 31, Operating lease liabilities Operating lease liabilities, current Operating lease liabilities $ 2,628 $ 2,419 Operating lease liabilities, non-current Operating lease liabilities, net of current portion 13,007 13,483 Total Operating lease liabilities $ 15,635 $ 15,902 Finance lease liabilities Finance lease liabilities, current Accrued liabilities $ 520 $ 554 Finance lease liabilities, non-current Other long-term liabilities 680 730 Total Finance lease liabilities $ 1,200 $ 1,284 Lease costs during the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended Lease costs Classification 2022 2021 Finance lease cost Amortization expense $ 161 $ 127 Finance lease cost Interest for finance lease $ 21 $ 14 Operating lease cost Operating lease expense $ 915 $ 878 Cash paid for amounts included in the measurement of lease liabilities during the three months ended March 31, 2022 and 2021 was as follows (in thousands): Three Months Ended Cash paid for amounts included in the measurement of lease liabilities Classification 2022 2021 Operating cash flow Finance lease $ 21 $ 14 Financing cash flow Finance lease $ 150 $ 115 Operating cash flow Operating lease $ 792 $ 772 Facility leases Maturities of facility leases were as follows as of March 31, 2022 (in thousands): As of March 31, 2022 Amount Remainder of 2022 $ 2,469 2023 3,332 2024 2,904 2025 2,875 2026 2,970 2027 and thereafter 3,338 Total lease payments 17,888 Less: imputed interest 2,253 Present value of lease liabilities $ 15,635 Vehicle Leases As of March 31, 2022, the Company was committed to minimum lease payments for vehicles leased under long-term non-cancelable finance leases as follows (in thousands): As of March 31, 2022 Amount Remainder of 2022 $ 491 2023 349 2024 411 2025 21 2026 1 Total lease payments 1,273 Less: imputed interest 73 Present value of lease liabilities $ 1,200 Weighted-average remaining lease term and discount rate, as of March 31, 2022, were as follows: Lease Term and Discount Rate March 31, 2022 Weighted-average remaining lease term (years) Operating leases 5.5 Finance leases 2.1 Weighted-average discount rate Operating leases 4.7 % Finance leases 6.6 %
Leases	LeasesThe Company is a party to certain operating and finance leases for vehicles, office space and storage facilities. The Company’s operating leases consist of office space, as well as storage facilities and finance leases consist of automobiles. The Company’s leases generally have remaining terms of one The Company determines if a contract contains a lease at inception. Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent the right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, the Company estimates the incremental secured borrowing rates corresponding to the maturities of the leases. The Company based the rate estimates on prevailing financial market conditions, credit analysis, and management judgment. The Company recognizes expense for these leases on a straight-line basis over the lease term. Additionally, tenant incentives used to fund leasehold improvements are recognized when earned and reduce the Company’s right-of-use (“ROU”) asset related to the lease. These are amortized through the ROU asset as reductions of expense over the lease term. Supplemental balance sheet information related to leases was as follows (in thousands): Leases Classification March 31, December 31, Assets Right-of-use assets Operating lease assets $ 14,330 $ 14,627 Finance lease Property and equipment, net 403 392 Total leased assets $ 14,733 $ 15,019 Liabilities Classification March 31, December 31, Operating lease liabilities Operating lease liabilities, current Operating lease liabilities $ 2,628 $ 2,419 Operating lease liabilities, non-current Operating lease liabilities, net of current portion 13,007 13,483 Total Operating lease liabilities $ 15,635 $ 15,902 Finance lease liabilities Finance lease liabilities, current Accrued liabilities $ 520 $ 554 Finance lease liabilities, non-current Other long-term liabilities 680 730 Total Finance lease liabilities $ 1,200 $ 1,284 Lease costs during the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended Lease costs Classification 2022 2021 Finance lease cost Amortization expense $ 161 $ 127 Finance lease cost Interest for finance lease $ 21 $ 14 Operating lease cost Operating lease expense $ 915 $ 878 Cash paid for amounts included in the measurement of lease liabilities during the three months ended March 31, 2022 and 2021 was as follows (in thousands): Three Months Ended Cash paid for amounts included in the measurement of lease liabilities Classification 2022 2021 Operating cash flow Finance lease $ 21 $ 14 Financing cash flow Finance lease $ 150 $ 115 Operating cash flow Operating lease $ 792 $ 772 Facility leases Maturities of facility leases were as follows as of March 31, 2022 (in thousands): As of March 31, 2022 Amount Remainder of 2022 $ 2,469 2023 3,332 2024 2,904 2025 2,875 2026 2,970 2027 and thereafter 3,338 Total lease payments 17,888 Less: imputed interest 2,253 Present value of lease liabilities $ 15,635 Vehicle Leases As of March 31, 2022, the Company was committed to minimum lease payments for vehicles leased under long-term non-cancelable finance leases as follows (in thousands): As of March 31, 2022 Amount Remainder of 2022 $ 491 2023 349 2024 411 2025 21 2026 1 Total lease payments 1,273 Less: imputed interest 73 Present value of lease liabilities $ 1,200 Weighted-average remaining lease term and discount rate, as of March 31, 2022, were as follows: Lease Term and Discount Rate March 31, 2022 Weighted-average remaining lease term (years) Operating leases 5.5 Finance leases 2.1 Weighted-average discount rate Operating leases 4.7 % Finance leases 6.6 %
Leases	LeasesThe Company is a party to certain operating and finance leases for vehicles, office space and storage facilities. The Company’s operating leases consist of office space, as well as storage facilities and finance leases consist of automobiles. The Company’s leases generally have remaining terms of one The Company determines if a contract contains a lease at inception. Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent the right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, the Company estimates the incremental secured borrowing rates corresponding to the maturities of the leases. The Company based the rate estimates on prevailing financial market conditions, credit analysis, and management judgment. The Company recognizes expense for these leases on a straight-line basis over the lease term. Additionally, tenant incentives used to fund leasehold improvements are recognized when earned and reduce the Company’s right-of-use (“ROU”) asset related to the lease. These are amortized through the ROU asset as reductions of expense over the lease term. Supplemental balance sheet information related to leases was as follows (in thousands): Leases Classification March 31, December 31, Assets Right-of-use assets Operating lease assets $ 14,330 $ 14,627 Finance lease Property and equipment, net 403 392 Total leased assets $ 14,733 $ 15,019 Liabilities Classification March 31, December 31, Operating lease liabilities Operating lease liabilities, current Operating lease liabilities $ 2,628 $ 2,419 Operating lease liabilities, non-current Operating lease liabilities, net of current portion 13,007 13,483 Total Operating lease liabilities $ 15,635 $ 15,902 Finance lease liabilities Finance lease liabilities, current Accrued liabilities $ 520 $ 554 Finance lease liabilities, non-current Other long-term liabilities 680 730 Total Finance lease liabilities $ 1,200 $ 1,284 Lease costs during the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended Lease costs Classification 2022 2021 Finance lease cost Amortization expense $ 161 $ 127 Finance lease cost Interest for finance lease $ 21 $ 14 Operating lease cost Operating lease expense $ 915 $ 878 Cash paid for amounts included in the measurement of lease liabilities during the three months ended March 31, 2022 and 2021 was as follows (in thousands): Three Months Ended Cash paid for amounts included in the measurement of lease liabilities Classification 2022 2021 Operating cash flow Finance lease $ 21 $ 14 Financing cash flow Finance lease $ 150 $ 115 Operating cash flow Operating lease $ 792 $ 772 Facility leases Maturities of facility leases were as follows as of March 31, 2022 (in thousands): As of March 31, 2022 Amount Remainder of 2022 $ 2,469 2023 3,332 2024 2,904 2025 2,875 2026 2,970 2027 and thereafter 3,338 Total lease payments 17,888 Less: imputed interest 2,253 Present value of lease liabilities $ 15,635 Vehicle Leases As of March 31, 2022, the Company was committed to minimum lease payments for vehicles leased under long-term non-cancelable finance leases as follows (in thousands): As of March 31, 2022 Amount Remainder of 2022 $ 491 2023 349 2024 411 2025 21 2026 1 Total lease payments 1,273 Less: imputed interest 73 Present value of lease liabilities $ 1,200 Weighted-average remaining lease term and discount rate, as of March 31, 2022, were as follows: Lease Term and Discount Rate March 31, 2022 Weighted-average remaining lease term (years) Operating leases 5.5 Finance leases 2.1 Weighted-average discount rate Operating leases 4.7 % Finance leases 6.6 %

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The Company is named from time to time as a party to other legal proceedings, product liability, commercial disputes, employee disputes, and contractual lawsuits in the normal course of business. A liability and related charge are recorded to earnings in the Company’s consolidated financial statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including discussion with outside legal counsel. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no amount within the range is a better estimate than any other. If a material loss is reasonably possible, but not probable and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. The Company expenses legal fees as incurred. On January 31, 2020, the Company filed a lawsuit against Lutronic Aesthetics in the United States District Court for the Eastern District of California. Lutronic employs numerous former Company employees. The complaint against Lutronic generally alleges claims for (1) misappropriation of trade secrets in violation of state and federal law; (2) violation of the Racketeer Influenced and Corrupt Organizations Act (RICO); (3) interference with contractual relations; (4) interference with prospective economic advantage; (5) unfair competition; and (6) aiding and abetting. On March 13, 2020, the court entered a temporary restraining order against Lutronic generally prohibiting it from using or disseminating the Company's confidential, proprietary, or trade secret information. The order also prohibits Lutronic, for two years, from using such information for the purpose of soliciting, or conducting business with, certain specified customers. At the parties’ request, the Court subsequently entered a preliminary injunction providing for the same restrictions in the restraining order. On February 9, 2022, the Company filed a motion seeking leave from the court to file a second amended complaint. In addition to the above-referenced claims against Lutronic Aesthetics, the proposed amended complaint alleges additional claims against it, including (1) violation of the Lanham Act; (2) unlawful business practices; (3) false advertising; and (4) trademark infringement. The proposed amended complaint also seeks to add Lutronic Corporation (the Korean parent company of Lutronic Aesthetics) as an additional defendant, and also alleges against it the above-described claims for misappropriation of trade secrets, violation of RICO, interference with contractual relations and prospective economic advantage, unfair competition, and aiding and abetting. Discovery is ongoing and no trial date has been scheduled. As of March 31, 2022 and March 31, 2021, the Company had accrued $0.5 million and $0.4 million, respectively, related to various pending commercial and product liability lawsuits. The Company does not believe that a material loss in excess of accrued amounts is reasonably likely.

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	Debt Convertible notes, net of unamortized debt issuance costs In March 2021, the Company issued $138.3 million aggregate principal amount of convertible senior notes due on March 15, 2026 in a private placement offering. The convertible notes bear interest at a rate of 2.25% per year payable semiannually in arrears on March 15 and September 15 of each year, beginning on September 15, 2021. Upon conversion, the convertible notes will be convertible into cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. The convertible notes are presented as convertible notes, net of unamortized debt issuance costs, on the condensed consolidated balance sheet. Proceeds from the offering were $133.6 million, net of issuance costs, including initial purchasers fees. Initially, each $1,000 principal amount of Notes was convertible into 30.1427 shares of the Company’s common stock at a conversion price of $33.18 per share. The conversion rate for the convertible notes is subject to adjustment for certain events as set forth in the Indenture governing the convertible notes. The convertible notes will mature on March 15, 2026, unless earlier converted, redeemed, or repurchased in accordance with the terms of the convertible notes. No sinking fund is provided for the Notes. As of March 31, 2022, the net carrying amount of the Company’s convertible notes was $134.5 million and the unamortized debt issuance costs were $3.8 million. Holders may convert their Notes at their option prior to the close of business on the business day immediately preceding December 15, 2025, in multiples of $1,000 principal amount, only under the following circumstances: • During any fiscal quarter commencing after the fiscal quarter ending on June 30, 2021 (and only during such fiscal quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on and including, the last trading day of the immediately preceding fiscal quarter, is greater than or equal to 130% of the conversion price for the convertible notes on each applicable trading day; • During the five-business day period after any five consecutive trading day period (the “measurement period”) in which the “trading price” per $1,000 principal amount of convertible notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate on each such trading day; • The Company calls such convertible notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; or • Upon the occurrence of specified corporate events. On or after December 15, 2025, and until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes, in multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances. The circumstances described in the first bullet of the paragraph above were not met during the first quarter of 2022. As of March 31, 2022, the Notes are not convertible and this condition will remain until June 30, 2022. The notes may become convertible in future periods. Upon any conversion requests of the convertible notes, the Company would be required to pay or deliver, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at the Company’s election with respect to such conversion requests. To the extent there are any conversion requests during the twelve months ending March 31, 2023, the Company intends to settle such conversion requests in shares of common stock. Therefore, as of March 31, 2022, the convertible notes have been included as Long-term debt on the condensed consolidated balance sheet. The Company may not redeem the convertible notes prior to March 20, 2024. On or after March 20, 2024, the Company may redeem for cash all or any portion of the Notes, at the Company’s option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem fewer than all of the outstanding Notes, at least $50.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the relevant redemption notice date. If a specified corporate event occurs, note holders have the option to require the Company to repurchase any portion or all of their convertible notes in $1,000 principal increments for cash. The price for such repurchase is calculated as 100% of the principal amounts of Notes, plus accrued and unpaid interest to the day immediately preceding the Fundamental Change repurchase date. Additionally, holders of the Notes who convert in connection with a fundamental change are, under certain circumstances, entitled to an increase in conversion rate. The convertible notes are general senior unsecured obligations that rank senior to any of the Company’s indebtedness that is explicitly subordinated to the Notes. The Notes have equal rank in right of payment with all existing and future unsecured indebtedness that is not subordinated to the Notes. The Notes will be junior to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness. The Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The estimated fair value of the convertible notes was approximately $295.4 million as of March 31, 2022, which the Company determined through consideration of market prices. The fair value measurement is classified as Level 2, as defined in Note 3. The following table presents the outstanding principal amount and carrying value of the convertible notes (in thousands): March 31, December 31, Outstanding principal amount $ 138,250 $ 138,250 Unamortized debt issuance costs (3,788) (4,007) Carrying Value $ 134,462 $ 134,243 In connection with issuance of the convertible notes, the Company entered into capped call transactions with certain option counterparties. The capped call transactions are generally intended to reduce the potential dilution of the Company's common stock upon any conversion or settlement of the Notes or to offset any cash payment the Company is required to make in excess of the principal amount upon conversion of the Notes, as the case may be, with such reduction or offset subject to a cap based on the cap price. If the market price per share of the Company’s common stock exceeds the cap price of the capped calls transaction, then the Company’s stock would experience some dilution and/or the capped call would not fully offset the potential cash payments, in each case to the extent the then-market price per share of its common stock exceeds the cap price. Under the capped call transactions, the Company purchased from the option counterparties capped call options that in the aggregate relate to the total number of shares of the Company's common stock underlying the convertible notes, with a strike price equal to the conversion price of the convertible notes and with an initial cap price equal to $45.5350, which represents a 75% premium over the last reported sale price of the Company's common stock of $26.02 per share on March 4, 2021, with certain adjustments to the settlement terms that reflect standard anti-dilution provisions. The capped call transactions expire over 40 consecutive scheduled trading days ended on March 12, 2026. The capped calls were purchased for $16.1 million. The Company evaluated the capped call transaction under authoritative accounting guidance and determined that it should be accounted for as a separate transaction and classified as a net reduction to Additional paid-in capital within stockholders’ equity with no recurring fair value measurement recorded. The Company early adopted ASU 2020-6, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40) on January 1, 2021. In accordance with Subtopic 470-20 and 815-40, as revised by ASU 2020-6, the Company records the convertible notes in long-term debt with no separation between the Notes and the conversion option. Each reporting period, the Company will determine whether any criteria is met for the note holders to have the option to redeem the Notes early, which could result in a change in the classification of the Notes to current liabilities. Debt Issuance Cost The issuance costs related to the convertible notes are presented in the condensed consolidated balance sheet as a direct deduction from the carrying amount of the convertible notes. The issuance costs are amortized using an effective interest method basis over the term of the convertible notes and accordingly the Company recorded approximately $0.2 million of amortization of debt issuance costs during the three months ended March 31, 2022. The effective interest rate on the convertible notes is 2.97%. Interest expense for the three months ended March 31, 2022, including the amortization of debt issuance cost, totaled approximately $1.0 million. Loan and Security Agreement On July 9, 2020, the Company entered into a Loan and Security Agreement with Silicon Valley Bank for a four-year secured revolving loan facility (“SVB Revolving Line of Credit”) in an aggregate principal amount of up to $30.0 million. The SVB Revolving Line of Credit matures on July 9, 2024. In order to draw on the full amount of the SVB Revolving Line of Credit, the Company must satisfy certain liquidity ratios. If the Company is unable to meet these liquidity ratios, then availability under the revolving line is calculated as 80% of the Company’s qualifying accounts receivable. The proceeds of the revolving loans may be used for general corporate purposes. The Company’s obligations under the Loan and Security Agreement with Silicon Valley Bank are secured by substantially all of the assets of the Company. Interest on principal amount outstanding under the revolving line shall accrue at a floating per annum rate equal to the greater of either 1.75% above the Prime Rate or five percent (5.0%). The Company paid a non-refundable revolving line commitment fee of $0.3 million, on the effective date of the Loan and Security Agreement with Silicon Valley Bank of July 9, 2020, and the Company is required to pay an anniversary fee of $0.3 million on each twelve-month anniversary of the effective date of the Loan and Security Agreement. The Loan and Security Agreement with Silicon Valley Bank contains customary affirmative covenants, such as financial statement reporting requirements and delivery of borrowing base certificates, as well as customary covenants that restrict the Company’s ability to, among other things, incur additional indebtedness, sell certain assets, guarantee obligations of third parties, declare dividends, or make certain distributions, and undergo a merger or consolidation or certain other transactions. The Loan and Security Agreement also contains certain financial covenants, including maintaining a quarterly minimum revenue of $90.0 million, determined in accordance with GAAP on a trailing twelve-month basis, but which is only applicable if the Company has an outstanding balance under the loan facility. On March 4, 2021, the Loan and Security Agreement dated July 9, 2020 was amended to (i) permit the Company to issue the convertible notes and perform its obligations in connection therewith, and (ii) permit the Capped Call transactions. On or about May 28, 2021, the Loan and Security Agreement was amended. The amendment removed the quarterly minimum revenue requirement but kept in place the other financial covenants. As of March 31, 2022, the Company had not drawn on the SVB Revolving Line of Credit and the Company is in compliance with all financial covenants of the SVB Revolving Line of Credit. The Paycheck Protection Program (PPP) Loan On April 22, 2020, the Company received loan proceeds of $7.2 million pursuant to the Paycheck Protection Program (the “PPP”) under the CARES Act. The loan, which was in the form of a promissory note dated April 21, 2020, between the Company and Silicon Valley Bank as the lender, originally matured on April 21, 2022 and bore interest at a fixed rate of 1.00% per annum, payable monthly commencing September 2021. There was no prepayment penalty. Under the terms of the PPP, all or a portion of the principal may have been forgiven if the loan proceeds were used for qualifying expenses as described in the CARES Act, such as payroll costs, benefits, rent, and utilities. The PPP loan and related accrued interest were forgiven in June 2021 under the provisions of the CARES Act, and a $7.2 million gain on forgiveness was recorded as Gain on extinguishment of PPP loan in the condensed consolidated statement of operations.

Segment reporting

Segment reporting	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Reporting	Segment reporting Segment reporting is based on the “management approach,” following the method that management organizes the Company’s reportable segments for which separate financial information is made available to, and evaluated regularly by, the chief operating decision maker in allocating resources and in assessing performance. The Company’s chief operating decision makers ("CODM") are its Chief Executive Officer ("CEO") and Chief Financial Officer (“CFO”), who make decisions on allocating resources and in assessing performance. The CEO and CFO review the Company's consolidated results as one operating segment. In making operating decisions, the CODM primarily considers consolidated financial information, accompanied by disaggregated information about revenues by geography and product. All of the Company’s principal operations and decision-making functions are located in the U.S. The Company’s CODM view its operations, manages its business, and uses one measurement of profitability for the one operating segment - which sells aesthetic medical equipment and services, and distributes skincare products, to qualified medical practitioners. Substantially all of the Company’s long-lived assets are located in the U.S. The following table presents a summary of revenue by geography and product category for the three months March 31, 2022 and 2021 (in thousands): Three Months Ended 2022 2021 Revenue mix by geography: United States $ 24,474 $ 18,948 Japan 17,503 16,555 Asia, excluding Japan 3,609 1,989 Europe 4,191 5,001 Rest of the World, other than United States, Asia and Europe 8,237 7,175 Total consolidated revenue $ 58,014 $ 49,668 Revenue mix by product category: Products $ 36,514 $ 28,320 Consumables 3,903 2,925 Skincare 11,649 12,306 Total product revenue 52,066 43,551 Service 5,948 6,117 Total consolidated revenue $ 58,014 $ 49,668

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Operations and Principles of Consolidation	Description of Operations and Principles of Consolidation Cutera, Inc. (“Cutera” or the “Company”) is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. The Company develops, manufactures, distributes, and markets energy-based product platforms for use by medical practitioners, enabling them to offer safe and effective aesthetic treatments to their customers. The Company currently markets the following system platforms: AviClear, enlighten, excel, Secret PRO, Secret RF, truSculpt and xeo . Several of the Company’s systems offer multiple hand pieces and applications, providing customers the flexibility to upgrade their systems. The sales of (i) systems, system upgrades, and hand pieces (collectively “Systems” revenue); (ii) replacement hand pieces, Titan, truSculpt 3 D, truSculpt iD and truSculpt flex cycle refills, as well as single use disposable tips applicable to Secret PRO and Secret RF (“Consumables” revenue); and (iii) the distribution of third party manufactured skincare products (“Skincare” revenue); are collectively classified as “Products” revenue. In addition to Product revenue, the Company generates revenue from the sale of post-warranty service contracts, parts, detachable hand piece replacements (except for Titan, truSculpt 3D, truSculpt iD and truSculpt flex) and service labor for the repair and maintenance of products that are out of warranty, all of which are collectively classified as “Service” revenue. In March 2022, the Company received the U.S. Food and Drug Administration's 510(k) clearance of the AviClear acne treatment device ("AviClear"). AviClear is a laser treatment that offers a safe, prescription-free solution for acne. AviClear will be rolled out to physicians in the United States throughout 2022.
Basis of Presentation	Basis of Presentation In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements included in this report reflect all adjustments necessary for a fair statement of its condensed consolidated statements of financial position as of March 31, 2022 and December 31, 2021, and its condensed consolidated statements of results of operations, comprehensive income (loss), changes in equity, and cash flows for the three months ended March 31, 2022, and 2021. The December 31, 2021 condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (“GAAP”). The results for interim periods are not necessarily indicative of results for the entire year or any other interim period. Presentation of certain prior year balances have been updated to conform with current year presentation. All intercompany accounts and transactions have been eliminated upon consolidation. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s previously filed audited financial statements and the related notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2022.
Risks and Uncertainties	Risks and Uncertainties The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company's products, stability of global financial markets, cybersecurity breaches and other disruptions that could compromise the Company’s information or results, business disruptions that are caused by natural disasters or pandemic events, management of international activities, competition from substitute products and larger companies, ability to obtain and maintain regulatory approvals, government regulations and oversight, patent and other types of litigation, ability to protect proprietary technology from counterfeit versions of the Company's products, strategic relationships and dependence on key individuals. The COVID-19 outbreak and related variants have negatively affected the United States and global economies. The spread of the coronavirus has impacted the global economy broadly in 2021 and 2020, including restrictions on travel, shifting work forces to work remotely and quarantine policies put into place by businesses and governments, had a material economic effect on the Company’s business during the year ended December 31, 2021. Healthcare facilities in many countries effectively banned elective procedures and this had a significant impact on the Company. Many of the Company’s products are used in aesthetic elective procedures and as such, the bans on elective procedures substantially reduced the Company’s sales and marketing efforts in the early months of the pandemic and led the Company to implement cost control measures. Although the Company’s revenues and profits have improved as the economic outlook improved in 2021 and into 2022, the COVID-19 outbreak continues to be fluid, and the long-term impact on the Company's business due to COVID-19 is still uncertain. The Company cannot presently predict the scope and severity of any impacts in future periods from business shutdowns or disruptions due to the COVID-19 pandemic, but the impact on economic activity including the possibility of recession or financial market instability could have a material adverse effect on the Company’s business, revenue, operating results, cash flows and financial condition. The Company continues to assess whether any impairment of its goodwill or its long-lived assets has occurred and has determined that no charges were necessary during the three months ended March 31, 2022. The Company will continue to monitor future conditions important to its assessment of potential impairment of its long-lived assets and goodwill, including the impacts of the COVID–19 pandemic and other ongoing impacts which are subject to uncertainty. In 2021, the Company experienced a significant increase in sales of skincare products under the exclusive distribution agreement with ZO Skin Health, Inc. (“ZO”), which allows the Company to sell ZO’s skincare products in Japan. The reason for the increase in skincare products sales may have been the result of the COVID-19 pandemic changing customers’ spending habits, resulting in customers purchasing aesthetic treatments that were able to be applied at home, due to limitations on in-person aesthetic procedures. Future growth in sales of skincare products depends on customers maintaining spending habits adopted during the COVID-19 pandemic. If customers revert to original spending habits after the COVID-19 pandemic, such changes may have a material adverse effect on the Company’s revenue, operating results, and cash flows.
Accounting Policies	Accounting Policies These unaudited condensed consolidated financial statements are prepared in accordance with the rules and regulations of the SEC applicable to interim financial statements. While these statements reflect all normal recurring adjustments that are, in the opinion of management, necessary for fair presentation of the results of the interim period, they do not include all of the information and footnotes required by GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the financial statement disclosures in its annual report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenue and expenses during the reported periods. Actual results could differ materially from those estimates. On an ongoing basis, management evaluates its estimates, including those related to warranty obligations, sales commission, allowance for credit losses, sales allowances, fair value of investments, valuation of inventories, fair value of goodwill, useful lives of property and equipment, impairment testing for long-lived-assets, implicit and incremental borrowing rates related to the Company’s leases, variables used in calculating the fair value of the Company's equity awards, expected achievement of performance based vesting criteria, management performance bonuses, assumptions used in operating and sales-type lease classification, the standalone selling price of the Company's products and services, the period of benefit used to capitalize and amortize contract acquisition costs, variable consideration, contingent liabilities, recoverability of deferred tax assets, residual value of leased equipment, lease term and effective income tax rates. Management bases estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes , to remove certain exceptions and improve consistency of application, including, among other things, requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The Company adopted this guidance starting January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial position and results of operations. In August 2020, the FASB issued ASU No. 2020-6, Debt – Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815), to simplify the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the amendment, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the computation of diluted earnings per share. The Company early adopted the guidance on a prospective basis effective January 1, 2021. See Note 13 – Debt.

Cash, Cash Equivalents and Ma_2

Cash, Cash Equivalents and Marketable Investments (Tables)	3 Months Ended
	Mar. 31, 2022
Cash and Cash Equivalents [Abstract]
Summary of Cash and Cash Equivalents	The following table summarizes the Company's cash and cash equivalents and marketable investments (in thousands): Gross Gross Fair Amortized Unrealized Unrealized Market March 31, 2022 Cost Gains Losses Value Cash and cash equivalents $ 57,732 $ — $ — $ 57,732 Non-current restricted cash 700 — — 700 Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows 58,432 — — 58,432 Marketable investments - U.S. Treasury 74,058 — (11) 74,047 Total $ 132,490 $ — $ (11) $ 132,479 Gross Gross Fair Amortized Unrealized Unrealized Market December 31, 2021 Cost Gains Losses Value Cash and cash equivalents $ 164,164 $ — $ — $ 164,164 Non-current restricted cash 700 — — 700 Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows $ 164,864 $ — $ — $ 164,864
Summary of Restricted Cash and Cash Equivalents	The following table summarizes the Company's cash and cash equivalents and marketable investments (in thousands): Gross Gross Fair Amortized Unrealized Unrealized Market March 31, 2022 Cost Gains Losses Value Cash and cash equivalents $ 57,732 $ — $ — $ 57,732 Non-current restricted cash 700 — — 700 Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows 58,432 — — 58,432 Marketable investments - U.S. Treasury 74,058 — (11) 74,047 Total $ 132,490 $ — $ (11) $ 132,479 Gross Gross Fair Amortized Unrealized Unrealized Market December 31, 2021 Cost Gains Losses Value Cash and cash equivalents $ 164,164 $ — $ — $ 164,164 Non-current restricted cash 700 — — 700 Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows $ 164,864 $ — $ — $ 164,864
Summary of Available-for-Sale Securities	The following table summarizes the Company's cash and cash equivalents and marketable investments (in thousands): Gross Gross Fair Amortized Unrealized Unrealized Market March 31, 2022 Cost Gains Losses Value Cash and cash equivalents $ 57,732 $ — $ — $ 57,732 Non-current restricted cash 700 — — 700 Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows 58,432 — — 58,432 Marketable investments - U.S. Treasury 74,058 — (11) 74,047 Total $ 132,490 $ — $ (11) $ 132,479 Gross Gross Fair Amortized Unrealized Unrealized Market December 31, 2021 Cost Gains Losses Value Cash and cash equivalents $ 164,164 $ — $ — $ 164,164 Non-current restricted cash 700 — — 700 Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows $ 164,864 $ — $ — $ 164,864 The following table summarizes the contractual maturities of the Company’s available-for-sale securities, classified as marketable investments, as of March 31, 2022 (in thousands): March 31, 2022 Amount Due in less than one year $ 74,058

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Assets Measured and Recognized at Fair Value on a Recurring Basis	As of March 31, 2022, financial assets measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above were as follows (in thousands): March 31, 2022 Level 1 Level 2 Level 2 Cash equivalents: Money market funds $ 948 $ — $ — Marketable investments: Available-for-sale securities 74,047 — — Total $ 74,995 $ — $ —

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventories	As of March 31, 2022 and December 31, 2021, inventories consist of the following (in thousands): March 31, December 31, Raw materials $ 31,134 $ 24,035 Work in process 2,902 2,124 Finished goods 17,644 13,344 Total $ 51,680 $ 39,503
Schedule of Accrued Liabilities	As of March 31, 2022 and December 31, 2021, accrued liabilities consist of the following (in thousands): March 31, December 31, Bonus and payroll-related accruals $ 16,639 $ 21,649 Sales and marketing accruals 3,678 4,808 Accrued inventory in transit 3,530 4,265 Product warranty 3,874 3,947 Accrued sales tax 9,853 9,110 Other accrued liabilities 10,470 10,321 Total $ 48,044 $ 54,100

Product Warranty (Tables)

Product Warranty (Tables)	3 Months Ended
	Mar. 31, 2022
Product Warranties Disclosures [Abstract]
Product Warranty Liability Accrual	The following table provides the changes in the product warranty accrual for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended 2022 2021 Beginning Balance $ 3,947 $ 2,908 Add: Accruals for warranties issued during the period 1,462 1,525 Less: Settlements made during the period (1,535) (1,082) Ending Balance $ 3,874 $ 3,351

Deferred Revenue (Tables)

Deferred Revenue (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Summary of Deferred Service Contract Revenue	The following table provides changes in the deferred revenue balance for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended 2022 2021 Beginning balance $ 10,825 $ 11,237 Add: Payments received 4,864 4,929 Less: Revenue (458) (445) Less: Revenue recognized from beginning balance (4,167) (3,984) Ending balance $ 11,064 $ 11,737

Stockholders' Equity and Stoc_2

Stockholders' Equity and Stock-based Compensation Expense (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of Activity under the 2019 Plan	Activity under the Company's equity incentive plans is summarized as follows: Shares Balance, December 31, 2021 947,347 RSUs granted (95,761) PSUs granted (90,658) Options granted (207,062) Stock awards canceled / forfeited / expired 22,568 Options canceled / forfeited / expired 2,072 Balance, March 31, 2022 578,506 Options Outstanding Number of Weighted- Weighted Average Remaining Term Balance, December 31, 2021 287,175 $ 25.89 4.92 Options granted 207,062 $ 35.34 Options exercised (7,459) $ 20.24 Options canceled / forfeited / expired (2,072) $ 32.87 Balance, March 31, 2022 484,706 $ 29.99 6.88 Stock Awards Outstanding Number of Awards Outstanding Weighted Average Grant Date Fair Value per Share Balance, December 31, 2021 1,032,904 $ 35.00 RSUs granted 95,761 $ 39.53 PSUs granted 90,658 $ 34.16 Awards released (190,967) $ 28.04 Stock awards canceled / forfeited / expired (21,081) $ 40.00 Balance, March 31, 2022 1,007,275 $ 36.57
Summary of Stock-based Compensation Expense	Stock-based compensation expense by department recognized during the three months ended March 31, 2022 and 2021 was as follows (in thousands): Three Months Ended 2022 2021 Cost of revenue $ 459 $ 144 Sales and marketing 576 721 Research and development 980 301 General and administrative 2,028 680 Total stock-based compensation expense $ 4,043 $ 1,846

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss	The following table sets forth the computation of basic and diluted net loss and the weighted average number of shares used in computing basic and diluted net loss per share (in thousands, except per share data): Three Months Ended 2022 2021 Numerator: Net loss used in calculating net loss per share, basic and diluted $ (15,142) $ (359) Denominator: Weighted average shares of common stock outstanding used in computing net loss per share, basic 18,080 17,768 Dilutive effect of incremental shares and share equivalents: Options — — RSUs — — PSUs — — ESPP — — Weighted average shares of common stock outstanding used in computing net loss per share, diluted 18,080 17,768 Net loss per share: Net loss per share, basic $ (0.84) $ (0.02) Net loss per share, diluted $ (0.84) $ (0.02)
Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share	The following numbers of shares outstanding, prior to the application of the treasury stock method and the if-converted method, were excluded from the computation of diluted net loss per common share for the periods presented because including them would have had an anti-dilutive effect (in thousands): Three Months Ended 2022 2021 Capped call 4,167 4,167 Convertible notes 4,167 4,167 Options to purchase common stock 485 245 Restricted stock units 526 585 Performance stock units 482 92 Employee stock purchase plan shares 32 30 Total 9,859 9,286

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases was as follows (in thousands): Leases Classification March 31, December 31, Assets Right-of-use assets Operating lease assets $ 14,330 $ 14,627 Finance lease Property and equipment, net 403 392 Total leased assets $ 14,733 $ 15,019 Liabilities Classification March 31, December 31, Operating lease liabilities Operating lease liabilities, current Operating lease liabilities $ 2,628 $ 2,419 Operating lease liabilities, non-current Operating lease liabilities, net of current portion 13,007 13,483 Total Operating lease liabilities $ 15,635 $ 15,902 Finance lease liabilities Finance lease liabilities, current Accrued liabilities $ 520 $ 554 Finance lease liabilities, non-current Other long-term liabilities 680 730 Total Finance lease liabilities $ 1,200 $ 1,284 Weighted-average remaining lease term and discount rate, as of March 31, 2022, were as follows: Lease Term and Discount Rate March 31, 2022 Weighted-average remaining lease term (years) Operating leases 5.5 Finance leases 2.1 Weighted-average discount rate Operating leases 4.7 % Finance leases 6.6 %
Summary of Lease Costs	Lease costs during the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended Lease costs Classification 2022 2021 Finance lease cost Amortization expense $ 161 $ 127 Finance lease cost Interest for finance lease $ 21 $ 14 Operating lease cost Operating lease expense $ 915 $ 878 Cash paid for amounts included in the measurement of lease liabilities during the three months ended March 31, 2022 and 2021 was as follows (in thousands): Three Months Ended Cash paid for amounts included in the measurement of lease liabilities Classification 2022 2021 Operating cash flow Finance lease $ 21 $ 14 Financing cash flow Finance lease $ 150 $ 115 Operating cash flow Operating lease $ 792 $ 772
Summary of Maturities of Facility Leases	Maturities of facility leases were as follows as of March 31, 2022 (in thousands): As of March 31, 2022 Amount Remainder of 2022 $ 2,469 2023 3,332 2024 2,904 2025 2,875 2026 2,970 2027 and thereafter 3,338 Total lease payments 17,888 Less: imputed interest 2,253 Present value of lease liabilities $ 15,635
Summary of Minimum Finance Lease Payments	As of March 31, 2022, the Company was committed to minimum lease payments for vehicles leased under long-term non-cancelable finance leases as follows (in thousands): As of March 31, 2022 Amount Remainder of 2022 $ 491 2023 349 2024 411 2025 21 2026 1 Total lease payments 1,273 Less: imputed interest 73 Present value of lease liabilities $ 1,200

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Summary of Convertible Notes	The following table presents the outstanding principal amount and carrying value of the convertible notes (in thousands): March 31, December 31, Outstanding principal amount $ 138,250 $ 138,250 Unamortized debt issuance costs (3,788) (4,007) Carrying Value $ 134,462 $ 134,243

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Summary of Revenue by Geography	The following table presents a summary of revenue by geography and product category for the three months March 31, 2022 and 2021 (in thousands): Three Months Ended 2022 2021 Revenue mix by geography: United States $ 24,474 $ 18,948 Japan 17,503 16,555 Asia, excluding Japan 3,609 1,989 Europe 4,191 5,001 Rest of the World, other than United States, Asia and Europe 8,237 7,175 Total consolidated revenue $ 58,014 $ 49,668 Revenue mix by product category: Products $ 36,514 $ 28,320 Consumables 3,903 2,925 Skincare 11,649 12,306 Total product revenue 52,066 43,551 Service 5,948 6,117 Total consolidated revenue $ 58,014 $ 49,668

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Narrative (Details)	Mar. 31, 2022country
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of countries in which entity utilizes a distributor network	42

Cash, Cash Equivalents and Ma_3

Cash, Cash Equivalents and Marketable Investments - Summary of Cash and Cash Equivalents and Available-for-Sale Securities (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Cash and cash equivalents	$ 57,732,000	$ 164,164,000
Restricted cash	700,000	700,000
Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows	58,432,000	164,864,000	$ 164,932,000	$ 47,047,000
Gross unrealized gains	0
Gross unrealized losses	(11,000)	$ 0
Total amortized cost	132,490,000
Total fair market value	132,479,000
Due in less than one year	74,058,000
Marketable investments - U.S. Treasury
Debt Securities, Available-for-sale [Line Items]
Amortized cost	74,058,000
Gross unrealized gains	0
Gross unrealized losses	(11,000)
Fair market value	$ 74,047,000

Cash, Cash Equivalents and Ma_4

Cash, Cash Equivalents and Marketable Investments - Narrative (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Gross unrealized losses	$ (11,000)	$ 0
Outstanding letter of credit	$ 700,000

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - Fair Value, Recurring $ in Thousands	Mar. 31, 2022USD ($)
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair market value	$ 74,047
Total assets	74,995
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair market value	0
Total assets	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair market value	0
Total assets	0
Money Market Funds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	948
Money Market Funds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0
Money Market Funds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 0

Balance Sheet Details - Invento

Balance Sheet Details - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 31,134	$ 24,035
Work in process	2,902	2,124
Finished goods	17,644	13,344
Total	$ 51,680	$ 39,503

Balance Sheet Details - Accrued

Balance Sheet Details - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Bonus and payroll-related accruals	$ 16,639	$ 21,649
Sales and marketing accruals	3,678	4,808
Accrued inventory in transit	3,530	4,265
Product warranty	3,874	3,947
Accrued sales tax	9,853	9,110
Other accrued liabilities	10,470	10,321
Total	$ 48,044	$ 54,100

Product Warranty - Summary of W

Product Warranty - Summary of Warranties (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning Balance	$ 3,947	$ 2,908
Add: Accruals for warranties issued during the period	1,462	1,525
Less: Settlements made during the period	(1,535)	(1,082)
Ending Balance	$ 3,874	$ 3,351

Deferred Revenue - Narrative (D

Deferred Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue balance, amount	$ 11.1
Costs for extended service contracts	$ 1.7	$ 2
Minimum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Extended service contract term	1 year
Maximum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Extended service contract term	4 years
Service | Minimum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Extended service contract term	1 year
Service | Maximum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Extended service contract term	3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue balance, percentage	88.00%
Expected timing of satisfaction, period	12 months

Deferred Revenue - Summary of D

Deferred Revenue - Summary of Deferred Service Contract Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Change in Contract with Customer, Liability [Roll Forward]
Beginning balance	$ 10,825	$ 11,237
Add: Payments received	4,864	4,929
Less: Revenue	(458)	(445)
Less: Revenue recognized from beginning balance	(4,167)	(3,984)
Ending balance	$ 11,064	$ 11,737

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Typical payment receipt, period post shipment	30 days
Training provided with sale of system, period	180 days
Contract with customer, liability	$ 11,064	$ 11,737	$ 10,825	$ 11,237
Minimum
Disaggregation of Revenue [Line Items]
Extended service contract term	1 year
Capitalized costs, expected period of benefit	2 years
Maximum
Disaggregation of Revenue [Line Items]
Extended service contract term	4 years
Capitalized costs, expected period of benefit	3 years
Sales and marketing
Disaggregation of Revenue [Line Items]
Amortization expense	$ 700	$ 500
Other Assets
Disaggregation of Revenue [Line Items]
Capitalized contract costs	$ 3,500		4,200
Service | Minimum
Disaggregation of Revenue [Line Items]
Extended service contract term	1 year
Service | Maximum
Disaggregation of Revenue [Line Items]
Extended service contract term	3 years
Loyalty
Disaggregation of Revenue [Line Items]
Contract with customer, liability	$ 300		$ 500
Skincare | Japan
Disaggregation of Revenue [Line Items]
Sale of third-party product, warranty period	90 days
Transferred over Time | Service
Disaggregation of Revenue [Line Items]
Revenue from performance obligations transferred to customers, percent	7.00%	12.00%

Stockholders' Equity and Stoc_3

Stockholders' Equity and Stock-based Compensation Expense - Narrative (Details)	3 Months Ended
	Mar. 31, 2022shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted in period (in shares)	207,062
Vesting period	4 years
Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percentage)	25.00%
Share-based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights (percentage)	3.00%
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	90,658
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	95,761
NQs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted in period (in shares)	207,062

Stockholders' Equity and Stoc_4

Stockholders' Equity and Stock-based Compensation Expense - Activity Of Options Outstanding Under the 2019 Plans (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Shares Available for Grant
Beginning balance (in shares)	947,347
Options granted (in shares)	(207,062)
Stock awards canceled (in shares)	22,568
Options canceled / forfeited / expired (in shares)	(2,072)
Ending balance (in shares)	578,506	947,347
Number of Stock Options Outstanding
Beginning balance (in shares)	287,175
Options granted (in shares)	207,062
Options exercised (in shares)	(7,459)
Options canceled / forfeited / expired (in shares)	(2,072)
Ending balance (in shares)	484,706	287,175
Weighted- Average Exercise Price
Beginning balance (in dollars per share)	$ 25.89
Granted (in dollars per share)	35.34
Options exercised (in dollars per share)	20.24
Options canceled / forfeited / expired (in dollars per share)	32.87
Ending balance (in dollars per share)	$ 29.99	$ 25.89
Weighted Average Remaining Term (in Years)
Weighted average remaining term (in years)	6 years 10 months 17 days	4 years 11 months 1 day
RSUs
Shares Available for Grant
Awards granted (in shares)	(95,761)
PSUs
Shares Available for Grant
Awards granted (in shares)	(90,658)

Stockholders' Equity and Stoc_5

Stockholders' Equity and Stock-based Compensation Expense - Activity of Stock Awards Outstanding Under the 2019 Plans (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Number of Awards Outstanding
Stock awards canceled / forfeited / expired (in shares)	(22,568)
Stock awards
Number of Awards Outstanding
Beginning balance (in shares)	1,032,904
Awards released (in shares)	(190,967)
Stock awards canceled / forfeited / expired (in shares)	(21,081)
Ending balance (in shares)	1,007,275
Weighted Average Grant Date Fair Value per Share
Beginning balance (in dollars per share) | $ / shares	$ 35
Awards released (in dollars per share) | $ / shares	28.04
Stock awards canceled / forfeited / expired (in dollars per share) | $ / shares	40
Ending balance (in dollars per share) | $ / shares	$ 36.57
PSUs
Number of Awards Outstanding
Milestone	90,658
Weighted Average Grant Date Fair Value per Share
Stock awards granted (in dollars per share) | $ / shares	$ 34.16
RSUs
Number of Awards Outstanding
Milestone	95,761
Weighted Average Grant Date Fair Value per Share
Stock awards granted (in dollars per share) | $ / shares	$ 39.53

Stockholders' Equity and Stoc_6

Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense By Department (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 4,043	$ 1,846
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	459	144
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	576	721
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	980	301
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,028	$ 680

Net Loss Per Share - Narrative

Net Loss Per Share - Narrative (Details)	3 Months Ended
	Mar. 31, 2022shares
Convertible Senior Notes Due 2026 | Convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Debt convertible to common shares (in shares)	4,167,232

Net Loss Per Share - Net Loss P

Net Loss Per Share - Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss used in calculating net income (loss) per share, basic	$ (15,142)	$ (359)
Net loss used in calculating net income (loss) per share, diluted	$ (15,142)	$ (359)
Denominator:
Weighted average shares of common stock outstanding used in computing net loss per share, basic (in shares)	18,080	17,768
Dilutive effect of incremental shares and share equivalents:
Weighted average shares of common stock outstanding used in computing net loss per share, diluted (in shares)	18,080	17,768
Net loss per share:
Net loss per share, basic (USD per share)	$ (0.84)	$ (0.02)
Net loss per share, diluted (USD per share)	$ (0.84)	$ (0.02)
Options
Dilutive effect of incremental shares and share equivalents:
Dilutive effect of share-based payment arrangements (in shares)	0	0
RSUs
Dilutive effect of incremental shares and share equivalents:
Dilutive effect of share-based payment arrangements (in shares)	0	0
PSUs
Dilutive effect of incremental shares and share equivalents:
Dilutive effect of share-based payment arrangements (in shares)	0	0
ESPP
Dilutive effect of incremental shares and share equivalents:
Dilutive effect of share-based payment arrangements (in shares)	0	0

Net Loss Per Share - Antidiluti

Net Loss Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	9,859	9,286
Capped call
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,167	4,167
Convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,167	4,167
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	485	245
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	526	585
Performance stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	482	92
Employee stock purchase plan shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	32	30

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 233	$ 258

Leases - Narrative (Details)

Leases - Narrative (Details)	Mar. 31, 2022
Lessee, Lease, Description [Line Items]
Operating leases renewal terms (up to)	5 years
Finance leases renewal terms (up to)	5 years
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms of operating leases	1 year
Remaining lease terms of finance leases	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms of operating leases	10 years
Remaining lease terms of finance leases	10 years

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets
Right-of-use assets	$ 14,330	$ 14,627
Finance lease	403	392
Total leased assets	$ 14,733	$ 15,019
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment, net	Property and equipment, net
Operating lease liabilities
Operating lease liabilities, current	$ 2,628	$ 2,419
Operating lease liabilities, non-current	13,007	13,483
Present value of lease liabilities	15,635	15,902
Finance lease liabilities
Finance lease liabilities, current	520	554
Finance lease liabilities, non-current	680	730
Total Finance lease liabilities	$ 1,200	$ 1,284
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued liabilities	Accrued liabilities
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities

Leases - Lease Costs (Details)

Leases - Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Finance lease cost, Amortization expense	$ 161	$ 127
Finance lease cost, Interest for finance lease	21	14
Operating lease cost	$ 915	$ 878

Leases - Cash Paid for Amounts

Leases - Cash Paid for Amounts Included in the Measurement of Lease Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating cash flow, Finance lease	$ 21	$ 14
Financing cash flow, Finance lease	150	115
Operating cash flow, Operating lease	$ 792	$ 772

Leases - Maturities of Operatin

Leases - Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Remainder of 2022	$ 2,469
2023	3,332
2024	2,904
2025	2,875
2026	2,970
2027 and thereafter	3,338
Total lease payments	17,888
Less: imputed interest	2,253
Present value of lease liabilities	$ 15,635	$ 15,902

Leases - Maturities of Finance

Leases - Maturities of Finance Leases Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Remainder of 2022	$ 491
2023	349
2024	411
2025	21
2026	1
Total lease payments	1,273
Less: imputed interest	73
Present value of lease liabilities	$ 1,200	$ 1,284

Leases - Lease Information (Det

Leases - Lease Information (Details)	Mar. 31, 2022
Weighted-average remaining lease term (years)
Operating leases	5 years 6 months
Finance leases	2 years 1 month 6 days
Weighted-average discount rate
Operating leases	4.70%
Finance leases	6.60%

Contingencies - Narrative (Deta

Contingencies - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2022	Mar. 31, 2021
Pending Litigation
Loss Contingencies [Line Items]
Accrued litigation liabilities	$ 0.5	$ 0.4

Debt - Narrative (Details)

Debt - Narrative (Details)	Jul. 09, 2020USD ($)	Apr. 22, 2020USD ($)	Jun. 30, 2021USD ($)	Mar. 31, 2021USD ($)day$ / shares$ / item	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)$ / shares$ / item	Dec. 31, 2021USD ($)	Mar. 04, 2021$ / shares
Debt Instrument [Line Items]
Cap price (in USD per per share) | $ / item				45.5350		45.5350
Premium over stock price (percent)				75.00%		75.00%
Stock price (in USD per share) | $ / shares								$ 26.02
Capped-call transaction term, consecutive trading days | day				40
Purchase of capped call				$ 16,100,000	$ 0	$ 16,134,000
Interest on Convertible notes					778,000	$ 191,000
Convertible Senior Notes Due 2026
Debt Instrument [Line Items]
Convertible debt, conversion ratio				0.0301427
Convertible Senior Notes Due 2026 | Common Stock
Debt Instrument [Line Items]
Conversion price (in dollars per share) | $ / shares				$ 33.18		$ 33.18
Loan and Security Agreement | Silicon Valley Bank | Revolving Credit Facility
Debt Instrument [Line Items]
Interest rate	5.00%
Debt instrument term	4 years
Maximum borrowing capacity	$ 30,000,000
Qualifying accounts receivable	80.00%
Commitment fee amount	$ 300,000
Anniversary fee amount	300,000
Quarterly minimum revenue	$ 90,000,000
Loan and Security Agreement | Silicon Valley Bank | Revolving Credit Facility | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.75%
PPP Loan
Debt Instrument [Line Items]
Interest rate		1.00%
Loan proceeds		$ 7,200,000
Gain on extinguishment of PPP loan			$ 7,200,000
Convertible Notes | Convertible Senior Notes Due 2026
Debt Instrument [Line Items]
Notes issued				$ 138,300,000		$ 138,300,000
Interest rate				2.25%		2.25%
Proceeds from convertible notes, net of unamortized debt issuance costs				$ 133,600,000
Carrying amount					134,462,000		$ 134,243,000
Unamortized debt issuance costs					3,800,000
Redemption threshold percentage of stock price trigger				130.00%
Redemption threshold trading days | day				20
Redemption threshold consecutive trading days | day				30
Redemption price, percentage				100.00%
Required outstanding amount not subject to redemption				$ 50,000,000		$ 50,000,000
Amortization of Debt Issuance Costs					$ 200,000
Effective interest rate during period					2.97%
Interest on Convertible notes					$ 1,000,000
Convertible Notes | Convertible Senior Notes Due 2026 | Occurrence of Fundamental Change
Debt Instrument [Line Items]
Redemption price, percentage				100.00%
Incremental repurchase amount				$ 1,000		$ 1,000
Convertible Notes | Convertible Senior Notes Due 2026 | Level 2
Debt Instrument [Line Items]
Convertible debt at fair value					$ 295,400,000
Convertible Notes | Convertible Senior Notes Due 2026, First Conversion Trigger
Debt Instrument [Line Items]
Conversion threshold trading days | day				20
Threshold Consecutive trading days | day				30
Conversion threshold percentage of stock price trigger				130.00%
Convertible Notes | Convertible Senior Notes Due 2026, Second Conversion Trigger
Debt Instrument [Line Items]
Conversion threshold trading days | day				5
Threshold Consecutive trading days | day				5
Conversion threshold percentage of stock price trigger				98.00%

Debt - Outstanding Debt and Car

Debt - Outstanding Debt and Carrying Value (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Unamortized debt issuance costs	$ (3,788)	$ (4,007)
Convertible Senior Notes Due 2026 | Convertible Notes
Debt Instrument [Line Items]
Outstanding principal amount	138,250	138,250
Unamortized debt issuance costs	(3,788)	(4,007)
Carrying Value	$ 134,462	$ 134,243

Segment Reporting - Narrative (

Segment Reporting - Narrative (Details)	3 Months Ended
	Mar. 31, 2022segment
Segment Reporting [Abstract]
Number of operating segments	1

Segment Reporting - Summary of

Segment Reporting - Summary of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Total net revenue	$ 58,014	$ 49,668
Total product revenue
Disaggregation of Revenue [Line Items]
Total net revenue	52,066	43,551
Products
Disaggregation of Revenue [Line Items]
Total net revenue	36,514	28,320
Consumables
Disaggregation of Revenue [Line Items]
Total net revenue	3,903	2,925
Skincare
Disaggregation of Revenue [Line Items]
Total net revenue	11,649	12,306
Service
Disaggregation of Revenue [Line Items]
Total net revenue	5,948	6,117
United States
Disaggregation of Revenue [Line Items]
Total net revenue	24,474	18,948
Japan
Disaggregation of Revenue [Line Items]
Total net revenue	17,503	16,555
Asia, excluding Japan
Disaggregation of Revenue [Line Items]
Total net revenue	3,609	1,989
Europe
Disaggregation of Revenue [Line Items]
Total net revenue	4,191	5,001
Rest of the World, other than United States, Asia and Europe
Disaggregation of Revenue [Line Items]
Total net revenue	$ 8,237	$ 7,175